https://doi.org/10.55788/1069a256
While randomised-controlled trials are the gold standard, real-world evidence provides crucial insights into the comparative effectiveness of therapies. As Prof. Dennis McGonagle (University of Leeds, UK) pointed out, there is a lack of real-world studies on advanced therapies in PsA [1]. The multinational, prospective PRO-SPIRIT study aimed to explore the real-world comparative effectiveness of biological or targeted synthetic DMARDs in PsA. Prof. McGonagle reported on treatment effectiveness at 3 and 12 months.
The study included 1,192 participants across 175 sites in 6 countries. The patients’ baseline characteristics and disease activity were similar across treatment groups, except for notable differences in disease duration. Disease duration was longer in participants treated with JAK inhibitors and ixekizumab and shorter in those treated with TNF inhibitors. Participants treated with the 150 mg secukinumab regimen were less bio-experienced with biological or targeted synthetic DMARDs.
IL-17A inhibitors showed significantly greater improvements in clinical Disease Activity Index for PsA (cDAPSA), tender joint counts, and swollen joint counts than IL-12/23 and IL-23 inhibitors at 3 months, indicating a faster response. Ixekizumab was as effective as TNF and JAK inhibitors in improving cDAPSA scores and tender/swollen joint counts at both 3 and 12 months (see Figure). At 12 months, about 20% of the participants achieved cDAPSA remission when treated with ixekizumab and TNF inhibitors compared with 12% of the participants treated with secukinumab, IL-12/23 inhibitors, and IL-23 inhibitors; at 12 months the IL-23 pathway inhibitors were catching up.
Figure: Change from baseline in the clinical Disease Activity for PsA (cDAPSA) [2]
BL, baseline; cDAPSA, clinical disease activity for psoriatic arthritis; IL-I, interleukin inhibitor; IXE, ixekizumab; JAKi, Janus kinase inhibitor; SEC, secukinumab; TNFi, tumour necrosis factor inhibitor.
The PRO-SPIRIT findings underscore the value of real-world evidence in complementing randomised-controlled trials and guiding clinical decisions for PsA management. “Almost 1 in 5 patients achieved remission with ixekizumab and TNF blockers at 12 months, corroborating the EULAR recommendations,” Prof. McGonagle concluded [1,2].
- Tillet W, et al. Early and maintained comparative effectiveness of five different classes of advanced therapies in a large multinational cohort of real-world PsA patients. LBA0002. EULAR 2024 Congress, 12–15 June, Vienna, Austria.
- Gossec L, et al. Ann Rheum Dis 2020;79:700-12.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA Next Article
Nipocalimab meets primary endpoint in Sjögren’s syndrome »
« Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA Next Article
Nipocalimab meets primary endpoint in Sjögren’s syndrome »
Table of Contents: EULAR 2024
Featured articles
Advanced therapies show promising results in PsA real-world study
Small protein targeting IL-17A effective in PsA management
Late-breaking Abstracts
Nipocalimab meets primary endpoint in Sjögren’s syndrome
Advanced therapies show promising results in PsA real-world study
Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA
Small protein targeting IL-17A effective in PsA management
Spotlight on Rheumatoid Arthritis
New JAK1 inhibitor outperforms placebo in active RA
Macrophage profiling in synovial tissue predicts treatment response in RA
Innovative app boosts mental health in patients with RA
What is New in Lupus and Scleroderma
Daratumumab shows promise in systemic lupus erythematosus
Severe lung involvement in SSc linked to anti-Ro/SSA antibodies
Early treatment with ambrisentan might prevent PAH development in patients with SSc
Crystal-related Disorders in 2024
More patients hit their uric acid target with febuxostat and ruzinurad combination
Tophaceous gout at higher mortality risk than non-tophaceous gout
JAK Inhibition in Giant Cell Arteritis
Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?
Giant cell arteritis: Upadacitinib may be an upcoming treatment option
Spotlight on Other Indications
AxSpA: Higher comorbidity burden worsens radiographic progression
Hope for a durable effective injection therapy in knee osteoarthritis
Dermatomyositis: Triple therapy with tacrolimus beats cyclosporin regimen
Best of the Posters
Less fracture risk with denosumab than bisphosphonates in pre-treated osteoporosis
Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease
Stopping DMARDs? These key factors predict RA flares
Related Articles
July 31, 2023
Bimekizumab: high rates of sustained response in PsA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com